I mean the National MS Society paid for the study. How much 3rd party does one need? Some competitors waited years on hopes of a MTA that didn't pan out so I understand why they might be suspicious but Alkon just mentioned John Hopkins for MS in March. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5834718/
Investors are here for AD and will find out shortly the answer. The closer it gets the more I like the idea of hitting the market the way AXSM did by holding other indications until after 2B success although I will take any news I get whenever it comes.